

# Curriculum Vitae

Name: Valdemar Priebe  
Birth date: 1989.06.27  
Title: PhD  
Nationality: Sweden  
Residence: Forchstrasse 151  
8132 Egg, Switzerland  
Mobile: +41 76 77 94 579  
Mail: [valdemar.priebe@kispi.uzh.ch](mailto:valdemar.priebe@kispi.uzh.ch)  
Languages: Swedish (native), English (fluent),  
Polish(fluent), German(fluent)



## Education

- 2014-2018**      **PhD in Life Sciences from University of Lausanne, Lymphoma and Genomics Unit at the Institute of Oncology Research, Bellinzona, Switzerland**
- 2011-2013**      **Degree of Master of Medical Science with a Major in Biomedicine at Karolinska Institutet, Stockholm, Sweden**
- 2008-2011**      **Bachelor of Medical Science with a Major in Biomedicine at Karolinska Institutet**

## Experience/Projects

- Sep 2019-current**      **Postdoctoral Fellow, University of Zurich, Leukemia Research Unit Balgrist and Department of Molecular Mechanism of Disease, Zurich, Switzerland**  
Project title: *"Targeting the transcriptional network architecture driven by the oncogenic TCF3-HLF fusion"*  
Mentor: *Prof.Dr.med. Jean-Pierre Bourquin, Prof. Raffaella Santoro*
- 2014-2018**      **PhD Candidate, Institute of Oncology Research, Bellinzona, Switzerland**  
Project title: *" Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type"*  
Mentor: *Dr.med. Francesco Bertoni*
- Jan-Nov 2013**      **Master Thesis, Department of Laboratory Medicine, Karolinska Institutet,**  
Project title: *"Aberrant expression of SOX11 in mantle cell lymphoma"*  
Mentor: *Dr. Agata Wasik*  
Group: *Prof. Birgitta Sander*
- Oct/2012-Jan/2013**      **Senior Research Project, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet**  
Project title: *"P18ARF, full length variant of p14ARF, interacts with p53 without MDM2 involvement"*  
Mentor: *Dr. Elena Kashuba*  
Group: *Prof. George Klein*
- Apr-Jun 2012**      **Junior Research Project Department of Microbiology, Tumor and Cell biology, Karolinska Institutet**  
Project title: *"Enzymatic activity assay of full length UCKL1/F538 and its C-terminus truncated variant"*  
Mentor: *Dr. Elena Kashuba*  
Group: *Prof. George Klein*
- Jan-Jun 2011**      **Bachelor Thesis, Exchange Studies, German Cancer Research Center, Heidelberg, Germany**  
Project title: *"Analysis of T cell signaling: activation-induced downregulation of TXNIP and increased IL-1 $\beta$  secretion"*.  
Mentor: *Dr. Karsten Gülow, Dr. Sabine Sass*  
Group: *Prof.Dr. Peter Krammer*

## **Certificates**

- Certificate in Laboratory Animal Science - FELASA C acquired 2012

## **Practical skills/Techniques.**

Cellular Biology: Cell line or primary cell cultures, isolation of primary cell from blood and lymphoid tissues, ELISA, Flow Cytometry, Immunocytochemistry, MTT assay.

Molecular Biology: RNA isolation, cDNA synthesis, Real-time qPCR, Chemical transfection, Physical transfection, ChIP, Protein Immunoprecipitation, Protein purification, Enzyme assay (radiometric and spectrophotometric assay), Electrophoresis, Western blot, Plasmid cloning, Viral transduction, shRNA and CRISPR/Cas9 knock out.

Basic bioinformatics: Gene Set Enrichment Analysis, Partek Anova software, R/Bioconductor.

## **Oral Presentation**

14<sup>th</sup> International Conference on Malignant Lymphoma (14-ICML) June 14-17 2017

V Priebe, EY Chung, L Cascione, I Kwee, A Arribas, G Sartori, S Napoli, A Rinaldi, AA Mensah, M Ponzoni, E Zucca, D Rossi, G Lenz, M Thome, F Bertoni. *ETS1 positively regulates FAIM3 in activated B cell-like (ABC) diffuse large B cell lymphoma (DLBCL)*. Hematological Oncology 2017; 35 (S2), 56-57

## **Teaching Experience**

**Nov 2019** Assistant organizer of Module BIO230 Cancer Stem/Propagating Cells and their Microenvironment at University of Zurich. In addition, supervision of master students for 3 weeks, instructing in experimental work: cell culture, cloning, CRISPR/Cas9 and flow cytometry.

## **Publications**

### Manuscripts

V Priebe, S Napoli, EYL Chung, L Cascione, I Kwee, A Arribas, G Sartori, A Rinaldi, AA Mensah, M Ponzoni, E Zucca, D Rossi, D Efremov, G Lenz, M Thome, F Bertoni. *Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type*. (Submitted)

F Spriano, C Tarantelli, E Gaudio, M Gerlach, V Priebe, L Cascione, E Bernasconi, A Targa, S Dirnhofer, A Stathis, E Zucca, F Bertoni. *Single and combined BTK and PI3K $\delta$  inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas*. BJH 2019

F Spriano, EY Chung, E Gaudio, C Tarantelli, L Cascione, S Napoli, K Jessen, L Carrassa, V Priebe, G Sartori, G Graham, S Selvanathan, A Cavalli, A Rinaldi, I Kwee, M Testoni, D Genini, B. Ye, E Zucca, A Stathis, B Lannutti, J Toretsky, and F Bertoni. *The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents*. Clinical Cancer Research 2019

BK. Sasi, S Turkalj, H Kalkan, E Bojnik, M Winiarska, V Priebe, F Bertoni, L Mansouri, R Rosenquist, DG Efremov. *Inhibition of SYK or BTK overcomes venetoclax resistance in SHP1 negative/BCL-2 positive diffuse large B cell lymphoma*. Leukemia 2019

C Tarantelli, L Zhang, E Curti, E Gaudio, F Spriano, V Priebe, L Cascione, A Arribas, E Zucca, D Rossi, A Stathis, F Bertoni. *The BTK inhibitor zanubrutinib (BGB-3111) is synergistic with other anti-lymphoma targeted agents*. Haematologica 2019; 104(7): e307–e309

M Testoni, EYL Chung, V Priebe, F Bertoni. *The transcription factor ETS1 in lymphomas: friend or foe?*. Leukemia & lymphoma 2015; 56 (7), 1975-1980

AM Wasik, V Priebe, M Lord, Å Jeppsson-Ahlberg, B Christensson, Birgitta Sander. *Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma*. Leukemia & lymphoma 2014; 56 (5), 1425-1431

## Abstracts

V Priebe, EY Chung, L Cascione, I Kwee, A Arribas, G Sartori, S Napoli, A Rinaldi, AA Mensah, M Ponzoni, E Zucca, D Rossi, G Lenz, M Thome, F Bertoni. *ETS1 positively regulates FAIM3 in activated B Cell-like (ABC) diffuse large B cell lymphoma (DLBCL)* Hematological Oncology 2017; 35 (S2), 56-57

G Sartori, S Napoli, L Cascione, V Priebe, A Rinaldi, F Bertoni. *The role of FLI1 in mRNA splicing and rRNA processing of diffuse large B cell lymphoma (DLBCL)* Clinical Lymphoma, Myeloma and Leukemia 2017; 17, S373

EY Chung, M Ponzoni, ZY Xu-Monette, L Cascione, V Priebe, E Gaudio, J Wang, J Shang, C Visco, G Bhagat, E Xucca, D Rossi, KH Young, F Bertoni. *ETS1 phosphorylation at Thr38 (pETS1) is associated with cell of origin (COO), cell cycle activation, and inferior outcome in diffuse large B cell lymphoma.* Hematological Oncology 2017; 35 (S2), 153-154

EY Chung, M Ponzoni, ZY Xu-Monette, V Priebe, L Cascione, E Gaudio, J Wang, J Shang, C Visco, G Bhagat, E Xucca, D Rossi, KH Young, F Bertoni. *ETS1 phosphorylation at threonine-38 is a marker of B cell receptor activation, associating with cell of origin and outcome in diffuse large B cell lymphoma.* Blood 2016; 128 (22), 1755-1755

EY Chung, V Priebe, E Gaudio, I Kwee, C Tarantelli, A Rinaldi, L Carrassa, M Testoni, L Cascione, M Broggin, JA Toretsky, E Zucca, F Bertoni. *Pre-clinical lymphoma models show high sensitivity to the small molecule Yk-4-279.* Hematological Oncology 2015; 33, 235-236

EYL Chung, V Priebe, E Gaudio, I Kwee, C Tarantelli, A Rinaldi, Laura Carrassa, Monica Testoni, Luciano Cascione, Massimo Broggin, Jeffrey A Toretsky, Emanuele Zucca, Francesco Bertoni. *The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models.* Cancer Research 2015; 75 (15 Supplement), 1654-1654

M Lord, A Wasik, V Priebe, A Jeppsson-Ahlberg, B Christensson, B Sander. *Detection of SOX11 protein by flow cytometry.* Haematologica 2014; 99, 139-139

## Contributions

“Targeting both BET and CREBBP/EP300 proteins with the novel dual inhibitor NEO2734 leads to more preclinical anti-tumor activity in diffuse large B cell lymphoma than with single BET or CREBBP/EP300 inhibitors” (Manuscript in preparation)

“The novel Protac MZI is active in ABC DLBCL and MCL lymphoma cell lines” (Manuscript in preparation)

“Preclinical evaluation of the NOTCH inhibitor CB-103 as single agent and in combination in models of human lymphoma” (Manuscript in preparation)

“The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent” (Manuscript in preparation)

## References

Division of Pathology, F46 Department of  
Laboratory Medicine Karolinska Institutet  
Prof. Birgitta Sander  
Phone: +46 8 585 810 44  
Email: [Birgitta.Sander@ki.se](mailto:Birgitta.Sander@ki.se)  
Relation: Group Leader, Mentor

Institute of Oncology Research, Università della  
Svizzera italiana  
Dr. Eugenio Gaudio  
Phone: +41 91 820 0388  
Email: [Eugenio.Gaudio@ior.usi.ch](mailto:Eugenio.Gaudio@ior.usi.ch)  
Relation: Mentor

Division of Pathology, F46 Department of  
Laboratory Medicine Karolinska Institutet  
Dr. Agata M. Wasik  
Phone: +46 8 5858 1044  
Email: [Agata.Wasik@ki.se](mailto:Agata.Wasik@ki.se)  
Relation: Mentor

Institute of Oncology Research, Università della  
Svizzera italiana  
Dr.med. Francesco Bertoni  
Phone: +41 91 8200 367  
Email: [Francesco.Bertoni@ior.usi.ch](mailto:Francesco.Bertoni@ior.usi.ch)  
Relation: Group Leader, Mentor